期刊文献+

艾滋病患者白念珠菌ERG11基因突变的研究 被引量:4

Mutation analysis of ERG 11 gene in Candida albicans isolates from patients with acquired immunodeficiency syndrome (AIDS)
原文传递
导出
摘要 目的 探讨艾滋病患者的白念珠菌唑类耐药株中唑类抗真菌药物(氟康唑、伊曲康唑、伏立康唑)的作用靶位基因ERG 11基因突变与耐药的关系.方法 用PCR对临床分离的93株白念珠菌的Erg11基因进行扩增、测序,DNAman软件将测序结果与基因库中的X13296进行比对,将突变碱基翻译为氨基酸,确定是否发生错义突变.结果 共检出40个碱基突变位点,包括27个同义突变位点和13个错义突变位点.耐一种药物的突变菌株中每株菌只发生一处错义突变或无错义突变,而耐二种或三种药物的菌株中每株菌还可以同时出现两处或三处错义突变.结论 ERG 11基因错义突变与白念珠菌耐药有关. Objective To investigate the relationship between the mutation of ERG11 gene,a target of azole antifungal drugs (fluconazole,itraconazole,voriconazole),and azole-resistance in Candida albicans isolates from patients with AIDS.Methods Ninety-three Candida albicans strains were isolated from patients with AIDS.DNA was extracted from these isolates,and ERG11 gene was amplified by PCR followed by bidirectional sequencing.DNAman software was used to compare the resultant sequence with the reference sequence of ERG11 gene (GenBank accession no.X13296).Then,different base sequences were translated into amino acid sequences to determine whether missense mutations occured.Results A total of 40 mutation sites were identified in these isolates,including 27 silent mutations and 13 missense mutations.One or no missense mutation was detected in Candida albicans strains resistant to 1 antifungal agent,while those resistant to 2 or 3 antifungal agents simultaneously harbored 2 or 3 missense mutations.Conclusion The missense mutations in ERG11 gene are probably connected with azole resistance in Candida albicans.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2012年第1期32-34,共3页 Chinese Journal of Dermatology
基金 基金项目:卫生部艾滋病防治应用性研究项目(WA-2006-08):新疆医科大学研究生创新基金(MC2010-15)
关键词 念珠菌 白色 基因 ERG11 氟康唑 伊曲康唑 伏立康唑 Candicla albicans Genes, ERGll Fluconazole Itraconazole Voriconazole
  • 相关文献

参考文献10

二级参考文献37

  • 1曹先伟,冀朝辉,万喆,李若瑜.白色念珠菌耐药株CYP51基因突变热点探讨[J].中华医院感染学杂志,2004,14(11):1215-1218. 被引量:11
  • 2陈端,单斌,骈淮燕,杜艳,郭翀.医院真菌感染1225例分析[J].中华检验医学杂志,2005,28(4):387-388. 被引量:44
  • 3王应斌,王宏,郭辉玉,赵永忠,罗深秋.白假丝酵母ERG11基因突变分析[J].第一军医大学学报,2005,25(11):1390-1393. 被引量:9
  • 4刘素玲,冉玉平,曾蔚,张浩,代亚玲,李明远,贾文祥.一种适用于PCR反应的酵母菌、无绿藻及丝状真菌DNA提取方法[J].中国真菌学杂志,2006,1(6):340-342. 被引量:28
  • 5徐永豪,李春阳.耐唑类药白念珠菌ERG11基因点突变[J].中国真菌学杂志,2006,1(6):370-373. 被引量:8
  • 6Loftier J, Hebart H, Schumacher U,et al. Comparison of different methods for extraction of DNA for fungal pathogens from cultures and blood. J Clin Microbial, 1997,35:3311-3312.
  • 7Yamakami Y. Evaluation of PCR for detection of DNA specific for aspergillus species in sera of patients with various forms of pulmonary Aspergillosis. J Clin Microbial, 1998,36: 3619-3623.
  • 8Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis, 1997, 24: 776-784.
  • 9Vandenbossche I, Vaneechoutte M, Vandevenne M, et al. Susceptibility testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for application in the routine laboratory. J Clin Microbiol, 2002, 40: 918-921.
  • 10AsaiyK,Tsuchimori N,Okonogi K,et al.Formation of azoleresistant Candida albicans by mutation of sterol 14-demethylase P450.Antimicrob Agents Chemother,1999,43:1163-1169.

共引文献15

同被引文献54

  • 1Podust LM, Poulos TL,Waterman MR. Crystal structure ofcytochrome P450 14alpha-sterol demethylase(CYP51) fromMycobacteriam tuberculosis in complex with azole inhibitors.Proc Natl Acad Sci USA, 2001,98:3068-3073.
  • 2Marichal P, Koymans L, Willemsens S, et al. Contributionof mutations in the cytochrome P450 14alpha-demethylase(Ergllp, Cyp51p) to azole resistance in Candida albicans.Microbiology, 1999,145 = 2701-2713.
  • 3Sanglard D, Ischer F,Koymans L, et al. Amino acidsubstitutions in the cytochrome P-450 lanosterol 14alpha-demethylase( CYP51A1) from azole-resistant Candidaalbicans clinical isolates contribute to resistance to azoleantifungal agents. Antimicrob Agents Chemother, 1998,42:241-253.
  • 4White TC. The presence of an R467K amino acidsubstitution and loss of allelic variation correlate with anazole-resistant ianosterol 14alpha demethylase in Candidaalbicans. Antimicrob Agents Chemother, 1997,41:1488-1494.
  • 5Franz R, Kelly SL,Lamb DC, et al. Multiple molecularmechanisms contribute to a stepwise development offluconazole resistance in clinical Candida albicans strains.Antimicrob Agents Chemother, 1998, 42:3065-3072.
  • 6Aoyama Y. Kudo M,Asai K,et al. Emergence offluconazole-resistant sterol 14-demethylase P450(CYP51) inCandida albicans is a model demonstrating the diversificationmechanism of P450. Arch Biochem Biophys, 2000,379:170-171.
  • 7Perea S, Lopez-Ribot JL, Kirkpatrick WR, et at. Prevalenceof molecular mechanisms of resistance to azole antifungalagents in Candida albicans strains displaying high-levelfluconazole resistance isolated from human immunodeficiencyvirus-infected patients. Antimicrob Agents Chemother,2001,45:2676-2684.
  • 8Chau AS, Mendrick CA, Sabatelli FJ,et al. Application ofreal-time quantitative PCR to molecular analysis of Candidaalbicans strains exhibiting reduced susceptibility to azoles.Antimicrob Agents Chemother, 2004 ,48:2124-2131.
  • 9Xiao L, Madison V,Chau AS, et al. Three-dimensionalmodels of wild-type and mutated forms of cytochrome P45014alpha-sterol demethylases from Aspergillus fumigatus andCandida albicans provide insights into posaconazole binding.Antimicrob Agents Chemother, 2004,48:568-574.
  • 10Kakeya H,Miyazaki Y i Miyazaki H,et al. Genetic analysisof azole resistance in the Darlington strain of Candidaalbicans. Antimicrob Agents Chemother, 2000,44:2985-2990.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部